Dengue-induced pancarditis manifestation of young female with systemic lupus erythematosus: case report
Abstract
Background: Lupus activity is associated with cardiac manifestation with varied clinical spectrum from asymptomatic disease-to-fulminant heart failure (HF) and cardiogenic shock. Pancardiac inflammation manifestation in systemic lupus erythematosus (SLE) patient with acute HF manifestation is relatively rare condition. Although, the most common cardiac involvement of SLE is pericarditis. However, cardiac involvement of SLE can affect all layers of the heart: endocardium as valvulitis, myocardium, and pericardium. Overt lupus myocarditis was a rare occurrence (5%-10%), but has a fatal outcome, and this was associated with worse prognostic. While, valvulitis manifestation of SLE is also rare compared to pericarditis, it accounts for less than 20% of SLE.
Case summary: A 39-year-old female presented with acute HF symptom with vasculitis sign phenomena and renal insufficiency. Laboratory result showed leukocytopenia and thrombocytopenia. Echocardiography finding marked for valvulitis, myocarditis, and pericarditis involvement. Rheumatology work-up was significant for SLE with high disease activity. Other serology work-up showed positive dengue virus IgM. The patient was diagnosed with dengue-induced pancarditis with lupus nephritis. The patient was administered corticosteroid, HF medication, and cyclosporin. After 3 months follow-up, we found significant improvement in clinical and echocardiography functional parameter.
Discussion: Systemic lupus erythematosus is a chronic…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.